NCT07615504

Brief Summary

Patients with interstitial lung diseases (ILD) suffer significant delays in obtaining a diagnosis, and objective evidence of support for immunosuppressive therapies, due to weaknesses in the diagnostic tests available in ILD clinics. This project will assess several non-invasive assessments, focusing on blood and breath based sampling, to identify candidate tests that may translate through to routine clinical use. The tests being assessed will be initially employed in Pigeon Fanciers, a group recognised to be at high risk of developing ILD compared to age matched controls, due to their regular exposure to a known cause of ILD. Candidate tests will also be assessed for change over time in this group. Tests which show promise will then be utilised in patients with ILD diagnoses, including those with severe respiratory failure, to assess their acceptability to patients and their ability to provide useful prognostic information, to allow powering of future definitive clinical trials.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
750

participants targeted

Target at P75+ for all trials

Timeline
117mo left

Started Jan 2026

Longer than P75 for all trials

Geographic Reach
1 country

3 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress4%
Jan 2026Jan 2036

Study Start

First participant enrolled

January 17, 2026

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

May 22, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 29, 2026

Completed
9.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 15, 2036

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 15, 2036

Last Updated

May 29, 2026

Status Verified

May 1, 2026

Enrollment Period

10 years

First QC Date

May 22, 2026

Last Update Submit

May 22, 2026

Conditions

Keywords

Interstitial Lung DiseaseLung fibrosisNon-invasive assessmentPigeon fanciersPrognosticationDiagnosis

Outcome Measures

Primary Outcomes (2)

  • Prediction of subsequent clinical outcomes

    The utilised tests will be examined for their ability to accurately predict the subsequent diagnostic label for ILD and clinical behaviour

    5 years

  • Acceptability to participants

    The tests employed will be assessed for their ease of performance and acceptability from a participant perspective

    5 years

Study Arms (3)

Pigeon Fanciers

Active Pigeon Fanciers

Clinic patients with ILD

Patients with established Interstitial Lung Disease attending clinic

Hospital patients with ILD

Patients with established Interstitial Lung Disease admitted due to their condition

Eligibility Criteria

Age18 Years - 90 Years
Sexall(Gender-based eligibility)
Gender Eligibility DetailsAll
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Active Pigeon Fanciers, or patients with ILD presenting to clinics or hospital services with severe respiratory failure due to ILD

You may qualify if:

  • To participate subjects will either have to be active Pigeon Fanciers, or will be either attending ILD clinics for management of their interstitial lung disease or will present acutely to hospital services with severe respiratory failure due to ILD.

You may not qualify if:

  • Unable to provide informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Winter Gardens

Blackpool, FY1 1HU, United Kingdom

RECRUITING

Ninewells Hospital

Dundee, DD21UB, United Kingdom

RECRUITING

Perth Royal Infirmary

Perth, PH1 1NX, United Kingdom

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood and breath samples

MeSH Terms

Conditions

Lung Diseases, InterstitialPulmonary FibrosisDisease

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesFibrosisPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Mark Spears, PhD FRCP

    NHS Tayside and University of Dundee

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mark Spears, PhD FRCP

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Consultant Respiratory Physician

Study Record Dates

First Submitted

May 22, 2026

First Posted

May 29, 2026

Study Start

January 17, 2026

Primary Completion (Estimated)

January 15, 2036

Study Completion (Estimated)

January 15, 2036

Last Updated

May 29, 2026

Record last verified: 2026-05

Locations